Related Experiment Video

Updated: Dec 15, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.8K

SETD1A Promotes Proliferation of Castration-Resistant Prostate Cancer Cells via FOXM1 Transcription

Liu Yang1, Mingli Jin1, Sung Jean Park1

  • 1Gachon Research Institute of Pharmaceutical Sciences, College of Pharmacy, Gachon University, 191 Hambakmoero, Yeonsu-gu, Incheon 21936, Korea.

Cancers
|July 8, 2020
PubMed

Insights

The histone methyltransferase SETD1A drives proliferation in metastatic castration-resistant prostate cancer (mCRPC) by regulating FOXM1. High SETD1A-FOXM1 expression correlates with poor patient prognosis, highlighting a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Androgen deprivation therapy (ADT) often leads to castration-resistant prostate cancer (CRPC).
  • Metastatic CRPC (mCRPC) presents significant challenges in treatment and patient outcomes.
  • Understanding the molecular drivers of mCRPC proliferation is crucial for developing new therapies.

Purpose of the Study:

  • To investigate the role of histone H3K4 methyltransferase SETD1A in the proliferation of metastatic castration-resistant prostate cancer (mCRPC).
  • To elucidate the regulatory mechanism of SETD1A in mCRPC, particularly its relationship with FOXM1.
  • To assess the clinical significance of SETD1A expression in prostate cancer prognosis.

Main Methods:

  • Analysis of SETD1A expression levels in prostate cancer cell lines and clinical samples.
  • Investigating the interaction between SETD1A, E2F1, and the FOXM1 promoter region.
  • Assessing the impact of SETD1A on the expression of stem cell factors (e.g., OCT4) and stem cell formation in mCRPC.
  • Correlating SETD1A-FOXM1 expression with patient survival data.

Main Results:

  • SETD1A expression is significantly higher in mCRPC cells compared to primary prostate cancer cells.
  • SETD1A promotes mCRPC cell proliferation by upregulating the transcription factor FOXM1.
  • SETD1A binds to the FOXM1 promoter region with E2F1, facilitating H3K4 trimethylation.
  • SETD1A is essential for stem cell factor expression and stem cell formation in mCRPC.
  • High expression of the SETD1A-FOXM1 pair is associated with poor prognosis in prostate cancer patients.

Conclusions:

  • SETD1A is a key regulator of mCRPC proliferation, primarily through the transcriptional control of FOXM1.
  • The SETD1A-FOXM1 axis represents a potential therapeutic target for mCRPC.
  • SETD1A's role in promoting stem cell characteristics may contribute to mCRPC tumor formation and progression.
Keywords:
FOXM1SETD1Acastration-resistantprostate cancer

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.1K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K